In last trading session, AnaptysBio Inc (NASDAQ:ANAB) saw 0.84 million shares changing hands with its beta currently measuring -0.18. Company’s recent per share price level of $18.51 trading at -$0.78 or -4.04% at ring of the bell on the day assigns it a market valuation of $567.64M. That closing price of ANAB’s stock is at a discount of -123.18% from its 52-week high price of $41.31 and is indicating a premium of 34.04% from its 52-week low price of $12.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.04 million shares which gives us an average trading volume of 1.02 million if we extend that period to 3-months.
For AnaptysBio Inc (ANAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.46 in the current quarter.
AnaptysBio Inc (NASDAQ:ANAB) trade information
Upright in the red during last session for losing -4.04%, in the last five days ANAB remained trading in the red while hitting it’s week-highest on Wednesday, 04/02/25 when the stock touched $18.51 price level, adding 6.61% to its value on the day. AnaptysBio Inc’s shares saw a change of 39.80% in year-to-date performance and have moved -2.32% in past 5-day. AnaptysBio Inc (NASDAQ:ANAB) showed a performance of 12.87% in past 30-days. Number of shares sold short was 9.8 million shares which calculate 12.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 45 to the stock, which implies a rise of 58.87% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 80. It follows that stock’s current price would drop -2.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2.65% for stock’s current value.
AnaptysBio Inc (ANAB) estimates and forecasts
This year revenue growth is estimated to fall -46.86% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.27M for the same. And 11 analysts are in estimates of company making revenue of 9.04M in the next quarter. Company posted 7.18M and 10.97M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.30% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -1.29% while estimates for its earnings growth in next 5 years are of -2.78%.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
Insiders are in possession of 4.41% of company’s total shares while institution are holding 121.94 percent of that, with stock having share float percentage of 127.56%. Investors also watch the number of corporate investors in a company very closely, which is 121.94% institutions for AnaptysBio Inc that are currently holding shares of the company. ECOR1 CAPITAL, LLC is the top institutional holder at ANAB for having 7.52 million shares of worth $188.48 million. And as of 2024-06-30, it was holding 27.4931 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 2.87 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.4936 of outstanding shares, having a total worth of $71.94 million.
On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 752.82 shares of worth $13.93 million or 2.45% of the total outstanding shares. The later fund manager was in possession of 668.95 shares on Dec 31, 2024 , making its stake of worth around $12.38 million in the company or a holder of 2.18% of company’s stock.
